Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.79 |
| ▸ | FLT1 | P17948 | 2/20 | 0.79 |
| ▸ | FLT4 | P35916 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 4/20 | 0.67 |
| ▸ | MET | P08581 | 4/20 | 0.67 |
| ▸ | TEK | Q02763 | 4/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | FGR | P09769 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fruquintinib SCHEMBL947183 | 0.88 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| Fruquintinib SCHEMBL29366206 | 0.88 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| Fruquintinib SCHEMBL29516397 | 0.88 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931688 | 0.88 | KDR (0.76) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931698 | 0.86 | KDR (0.83) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931690 | 0.86 | KDR (0.81) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931696 | 0.83 | KDR (0.78) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931697 | 0.82 | KDR (0.54) | KDRFLT1FLT4AURKAAURKB | |
| SCHEMBL945597 | 0.82 | KDR (0.73) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL12909830 | 0.82 | KDR (0.87) | KDRFLT1FLT4AURKAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297115-B1 | DIALKOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2297115-B1 | DIALKOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137797-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885FLT1 2/4885FLT4 1/4885 |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | FLT4, FLT1, CXCR4 | KDR 6/4885FLT1 2/4885FLT4 1/4885 |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885FLT1 2/4885FLT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.